Compare NVCR & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVCR | SUPN |
|---|---|---|
| Founded | 2000 | 2005 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 2.6B |
| IPO Year | 2015 | 2012 |
| Metric | NVCR | SUPN |
|---|---|---|
| Price | $13.35 | $47.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $28.42 | ★ $63.25 |
| AVG Volume (30 Days) | ★ 1.7M | 639.4K |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $642,269,000.00 | ★ $681,539,000.00 |
| Revenue This Year | $9.75 | $8.32 |
| Revenue Next Year | $5.62 | $23.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.17 | 4.54 |
| 52 Week Low | $10.70 | $29.16 |
| 52 Week High | $34.13 | $57.65 |
| Indicator | NVCR | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 60.37 | 53.47 |
| Support Level | $10.79 | $45.36 |
| Resistance Level | $13.94 | $47.26 |
| Average True Range (ATR) | 0.61 | 1.23 |
| MACD | 0.22 | 0.36 |
| Stochastic Oscillator | 80.48 | 92.10 |
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.